Valuentum Exclusive Analysis for the Discerning Investor

Elanco Buys Bayer’s Animal Health Unit, Gaining Scale and Greater Exposure to the “Humanization of Pets” Trend
On August 20, Elanco Animal Health Inc agreed to acquire Bayer AG’s animal health unit for $7.6 billion (at the time the deal was announced) through a cash and stock deal. This is a transformative deal for Elanco and one that will create a real competitor to Zoetis' and Merck’s animal health units. For Bayer, the company can now pivot to segments where it has stronger competitive advantages while also raising cash to cover potential Roundup-related legal liabilities (which could be enormous). We will be monitoring the space going forward but are staying firmly on the sidelines for now.

Jun 26, 2019

Another Pharmaceutical Giant Is Born
Image Source: AbbVie Inc – IR Presentation. The combination of AbbVie and Allergan seems to have been born out of the need to do something, anything, considering how dependent AbbVie is on Humira and Allergan is on Botox. We find the transaction interesting as it ties into our view that Big Pharma will continue getting bigger and bigger while the field gets smaller, but this doesn’t change on view on either Allergan or AbbVie. We aren’t considering shares of either company at this time.

May 28, 2019

From Nano Cap to Big Cap in Biotech
Image shown: Athersys' MultiStem therapy can improve the lives of millions of stroke victims.We cover some very interesting technologies in this piece, from a nano-cap company that could best be described as a call option, a stroke therapy firm that may improve the lives of millions, to a big cap genomic sequencing leader that has exposure to the development of a liquid biopsy test for cancer.

May 3, 2019

Dividend Increases/Decreases for the Week Ending May 3
Let's take a look at companies that raised/lowered their dividend this week.

Apr 30, 2019

Top-Weighted Visa Leaps to Mid-$160s, More Earnings Reports
Image: Visa has been the top-weighted idea in the Best Ideas Newsletter for as long as we can remember. In December 2017, when we migrated to weighting ranges for ideas in the newsletter portfolio, the company's "weight" was 8.6%. The image above shows its performance relative to the S&P 500 since then. Source (pdf).

Feb 22, 2019

Dividend Increases/Decreases for the Week Ending February 22
Let's take a look at companies that raised/lowered their dividend this week.

Jan 30, 2019

Novartis Closes Out Busy Year; Proposes Dividend Hike
Image Source: Novartis fourth quarter presentation. European pharmaceutical giant Novartis had a busy year in 2018 on its quest to renew its focus on medicines, and management is excited about its future growth trajectory. We continue to like its free cash flow generation and dividend growth potential.

Jan 3, 2019

Brace for More Volatility
Image shown: The S&P 500 ETF (SPY) since August of last year. The markets have broken through key support levels, and now support has become resistance. Volatility remains heightened since the low-vol ETN blew up in February.This article is the introduction to both the Dividend Growth Newsletter and High Yield Dividend Newsletter, both of which will be released today due to the holiday January 1.

Dec 31, 2018

Valuentum Stock Screeners
Brian Nelson provides members with an update on Valuentum's stock screeners and the significant number of forward-looking data we provide. This article was sent to members via email December 29.

Dec 20, 2018

Market Mayhem -- Alerts for Members
Dear members -- we released a number of emails today. Please read and let us know if you have any questions. We're here for you.

Valuentum Exclusive Analysis for the Discerning Investor Symbol Keyword

Member Login

Newsletters/Portfolios

Dividend Cushion

Stock Screens

Products & Tools

Value Trap

The Buying Index, VBI

Dividend Changes

Valuentum Exclusive Analysis for the Discerning Investor